MedTrace Logo

Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)

NCT01329380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403

Last updated 2019-04-03

Study results available
· View outcomes & findings →

Summary

This study of adalimumab (Humira) will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug:

* Unknown adverse drug reactions (especially important adverse drug reactions)
* Incidence and conditions of occurrence of adverse reactions in the clinical setting
* Factors that may affect the safety and effectiveness of Humira

Conditions

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-27
Primary Completion
2017-12-28
Completion
2017-12-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01329380 on ClinicalTrials.gov